Evidence map›Paper›PMID 41314981›Full record

ArticleJournal for immunotherapy of cancer2025

FXR-mediated antigen-specific CD8

Shanshan Liu, Zhixing Liang, Lisi Zhu, Yuhao Zheng, Haoyuan Yu, Shusen Ye, Texi Liang, Linzi Huang, Jiayi Ouyang, Yingjiao Cao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shanshan Liu *Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0009-0001-2905-3283
Zhixing Liang *Department of Hepatic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Lisi Zhu *Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Yuhao ZhengGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Haoyuan YuDepartment of Hepatic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Shusen YeInstitute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.
Texi LiangGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Linzi HuangGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Jiayi OuyangGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Yingjiao CaoDepartment of Immunology and Microbiology, Sun Yat-Sen University, Guangzhou, China ye_linsen@163.com yelilinlcmv@tmmu.edu.cn caoyj27@mail.sysu.edu.cn.
Lilin YeGuangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China ye_linsen@163.com yelilinlcmv@tmmu.edu.cn caoyj27@mail.sysu.edu.cn.
Linsen YeDepartment of Hepatic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China ye_linsen@163.com yelilinlcmv@tmmu.edu.cn caoyj27@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0001-9632-1949

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntrahepatic cholangiocarcinoma (ICC) offers limited opportunities for surgical treatment, and advanced-stage patients exhibit poor responses to immunotherapy. Therefore, the exploration of new therapeutic strategies is of paramount importance. The farnesoid X receptor (FXR) is a nuclear receptor that has been reported to regulate immune cells in recent years. However, whether FXR can regulate CD8

methodsThe function of FXR in CD8

resultsFXR was specifically overexpressed in exhausted CD8

conclusionsTogether, these data identify FXR as an immune checkpoint and support repurposing UDCA for ICC immunotherapy.

Indexed as

Bile Duct NeoplasmsCD8-Positive T-LymphocytesCholangiocarcinomaReceptors, Cytoplasmic and NuclearAnimalsCell Line, TumorHumansImmunotherapyMiceMice, KnockoutReceptor, Farnesoid X-ActivatedReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearCombination therapyPenile CancerT-LymphocytesTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Identifiers

PMID41314981
PMCPMC12666157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.